Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $30,212.72 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 346 shares of Twist Bioscience stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $30,212.72. Following the sale, the insider directly owned 119,346 shares in the company, valued at approximately $10,421,292.72. This trade represents a 0.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Wednesday, June 24th, Dennis Cho sold 14,205 shares of Twist Bioscience stock. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75.
• On Monday, June 8th, Dennis Cho sold 402 shares of Twist Bioscience stock. The stock was sold at an average price of $69.84, for a total value of $28,075.68.

Twist Bioscience Stock Up 3.3%

TWST opened at $99.84 on Friday. The stock’s 50 day moving average price is $67.01 and its 200 day moving average price is $51.44. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. The stock has a market cap of $6.22 billion, a P/E ratio of -75.07 and a beta of 2.23. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $104.23.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. During the same quarter last year, the firm posted ($0.66) EPS. The company’s revenue was up 19.3% compared to the same quarter last year. As a group, research analysts predict that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Institutional Trading of Twist Bioscience

Several institutional investors have recently modified their holdings of TWST. William Blair Investment Management LLC grew its holdings in Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after acquiring an additional 1,812,146 shares during the period. EdgePoint Investment Group Inc. lifted its holdings in Twist Bioscience by 71.1% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after acquiring an additional 1,696,377 shares during the last quarter. Artisan Partners Limited Partnership lifted its holdings in Twist Bioscience by 26.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after acquiring an additional 1,349,867 shares during the last quarter. Millennium Management LLC lifted its holdings in Twist Bioscience by 151.5% in the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after acquiring an additional 1,080,722 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in shares of Twist Bioscience by 12.4% during the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after purchasing an additional 832,687 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TWST. Piper Sandler began coverage on shares of Twist Bioscience in a report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday. Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a research report on Friday, May 22nd. Canaccord Genuity Group initiated coverage on shares of Twist Bioscience in a research note on Monday, June 15th. They issued a “buy” rating and a $90.00 price target for the company. Finally, Robert W. Baird upped their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $74.60.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.